Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Schizophrenia

  Free Subscription


28.11.2022

2 Br J Psychiatry
1 J Psychiatry Neurosci
1 Mol Psychiatry
1 Neurosci Lett
1 Psychiatr Clin North Am
15 Psychol Med
21 Schizophr Res


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Br J Psychiatry

  1. IKKOS G, Stanghellini G
    Sensibility and schizophrenia: Wilhelm Waiblinger on Friedrich Holderlin's life, poetry and madness - psychiatry in literature.
    Br J Psychiatry. 2022;221:739.
    PubMed        

  2. BUTLER E, Pillinger T, Brown K, Borgan F, et al
    Real-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study.
    Br J Psychiatry. 2022;221:740-747.
    PubMed         Abstract available


    J Psychiatry Neurosci

  3. MURILLO-GARCIA N, Barrio-Martinez S, Setien-Suero E, Soler J, et al
    Overlap between genetic variants associated with schizophrenia spectrum disorders and intelligence quotient: a systematic review.
    J Psychiatry Neurosci. 2022;47:E393-E408.
    PubMed         Abstract available


    Mol Psychiatry

  4. TAYLOR J, de Vries YA, van Loo HM, Kendler KS, et al
    Clinical characteristics indexing genetic differences in schizophrenia: a systematic review.
    Mol Psychiatry. 2022 Nov 18. doi: 10.1038/s41380-022-01850.
    PubMed         Abstract available


    Neurosci Lett

  5. GORNEROVA N, Brunovsky M, Klirova M, Novak T, et al
    The effect of Low-Frequency rTMS on Auditory Hallucinations, EEG Source Localization and Functional Connectivity in Schizophrenia.
    Neurosci Lett. 2022 Nov 22:136977. doi: 10.1016/j.neulet.2022.136977.
    PubMed         Abstract available


    Psychiatr Clin North Am

  6. FISCHER CE, Namasivayam A, Crawford-Holland L, Hakobyan N, et al
    Psychotic Disorders in the Elderly: Diagnosis, Epidemiology, and Treatment.
    Psychiatr Clin North Am. 2022;45:691-705.
    PubMed         Abstract available


    Psychol Med

  7. RABALLO A, Poletti M
    Overlooking the transition elephant in the ultra-high-risk room: are we missing functional equivalents of transition to psychosis?
    Psychol Med. 2022;52:184-187.
    PubMed         Abstract available

  8. OSBORNE KJ, Damme KSF, Gupta T, Dean DJ, et al
    Timing dysfunction and cerebellar resting state functional connectivity abnormalities in youth at clinical high-risk for psychosis.
    Psychol Med. 2021;51:1289-1298.
    PubMed         Abstract available

  9. KING M, Jones R, Petersen I, Hamilton F, et al
    Cigarette smoking as a risk factor for schizophrenia or all non-affective psychoses.
    Psychol Med. 2021;51:1373-1381.
    PubMed         Abstract available

  10. QUATTRONE D, Ferraro L, Tripoli G, La Cascia C, et al
    Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.
    Psychol Med. 2021;51:1329-1337.
    PubMed         Abstract available

  11. ZHANG T, Xu L, Chen Y, Wei Y, et al
    Conversion to psychosis in adolescents and adults: similar proportions, different predictors.
    Psychol Med. 2021;51:2003-2011.
    PubMed         Abstract available

  12. BALLESTEROS A, Sanchez Torres AM, Lopez-Ilundain J, Mezquida G, et al
    The longitudinal effect of antipsychotic burden on psychosocial functioning in first-episode psychosis patients: the role of verbal memory.
    Psychol Med. 2021;51:2044-2053.
    PubMed         Abstract available

  13. CSUKLY G, Szabo A, Polgar P, Farkas K, et al
    Fronto-thalamic structural and effective connectivity and delusions in schizophrenia: a combined DTI/DCM study.
    Psychol Med. 2021;51:2083-2093.
    PubMed         Abstract available

  14. SAMI M, Quattrone D, Ferraro L, Tripoli G, et al
    Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls.
    Psychol Med. 2021;51:2074-2082.
    PubMed         Abstract available

  15. VERDOUX H, Quiles C, Bon L, Chereau-Boudet I, et al
    Impact of anticholinergic load on functioning and cognitive performances of persons with psychosis referred to psychosocial rehabilitation centers.
    Psychol Med. 2021;51:2789-2797.
    PubMed         Abstract available

  16. LAVALLE L, Donde C, Gaweda L, Brunelin J, et al
    Impaired self-recognition in individuals with no full-blown psychotic symptoms represented across the continuum of psychosis: a meta-analysis.
    Psychol Med. 2021;51:2864-2874.
    PubMed         Abstract available

  17. PATEL GH, Arkin SC, Ruiz-Betancourt DR, DeBaun HM, et al
    What you see is what you get: visual scanning failures of naturalistic social scenes in schizophrenia.
    Psychol Med. 2021;51:2923-2932.
    PubMed         Abstract available

  18. JONES HJ, Hammerton G, McCloud T, Hines LA, et al
    Examining pathways between genetic liability for schizophrenia and patterns of tobacco and cannabis use in adolescence.
    Psychol Med. 2022;52:132-139.
    PubMed         Abstract available

  19. VAN OS J, Pries LK, Ten Have M, de Graaf R, et al
    Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway.
    Psychol Med. 2022;52:1910-1922.
    PubMed         Abstract available

  20. MILLGATE E, Hide O, Lawrie SM, Murray RM, et al
    Neuropsychological differences between treatment-resistant and treatment-responsive schizophrenia: a meta-analysis.
    Psychol Med. 2022;52:1-13.
    PubMed         Abstract available

  21. SMUCNY J, Lesh TA, Niendam TA, Ragland JD, et al
    Evidence for functional improvement in reward anticipation in recent onset schizophrenia after one year of coordinated specialty care.
    Psychol Med. 2022 Nov 24:1-8. doi: 10.1017/S0033291722003592.
    PubMed         Abstract available


    Schizophr Res

  22. KIRIHARA K, Fujioka M, Suga M, Kondo S, et al
    Betaine supplementation improves positive symptoms in schizophrenia.
    Schizophr Res. 2022;250:120-122.
    PubMed        

  23. INTSON K, Geissah S, McCullumsmith RE, Ramsey AJ, et al
    A role for endothelial NMDA receptors in the pathophysiology of schizophrenia.
    Schizophr Res. 2022;249:63-73.
    PubMed         Abstract available

  24. CHAUMETTE B, Sengupta SM, Lepage M, Malla A, et al
    A polymorphism in the glutamate metabotropic receptor 7 is associated with cognitive deficits in the early phases of psychosis.
    Schizophr Res. 2022;249:56-62.
    PubMed         Abstract available

  25. LEON-ORTIZ P, Reyes-Madrigal F, Kochunov P, Gomez-Cruz G, et al
    White matter alterations and the conversion to psychosis: A combined diffusion tensor imaging and glutamate (1)H MRS study.
    Schizophr Res. 2022;249:85-92.
    PubMed         Abstract available

  26. ZEPPILLO T, Schulmann A, Macciardi F, Hjelm BE, et al
    Functional impairment of cortical AMPA receptors in schizophrenia.
    Schizophr Res. 2022;249:25-37.
    PubMed         Abstract available

  27. QIAN N, Lipkin RM, Kaszowska A, Silipo G, et al
    Computational modeling of excitatory/inhibitory balance impairments in schizophrenia.
    Schizophr Res. 2022;249:47-55.
    PubMed         Abstract available

  28. ASAH S, Alganem K, McCullumsmith RE, O'Donovan SM, et al
    A bioinformatic inquiry of the EAAT2 interactome in postmortem and neuropsychiatric datasets.
    Schizophr Res. 2022;249:38-46.
    PubMed         Abstract available

  29. REDDY-THOOTKUR M, Kraguljac NV, Lahti AC
    The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies.
    Schizophr Res. 2022;249:74-84.
    PubMed         Abstract available

  30. BENESH JL, Mueller TM, Meador-Woodruff JH
    AMPA receptor subunit localization in schizophrenia anterior cingulate cortex.
    Schizophr Res. 2022;249:16-24.
    PubMed         Abstract available

  31. ROBERTS RC, McCollum LA, Schoonover KE, Mabry SJ, et al
    Ultrastructural evidence for glutamatergic dysregulation in schizophrenia.
    Schizophr Res. 2022;249:4-15.
    PubMed         Abstract available

  32. BROWN H, Ongur D, Smurawska L, Valcourt S, et al
    Inpatient - Outpatient transitions in first episode psychosis care.
    Schizophr Res. 2022;250:123-124.
    PubMed        

  33. ZHANG W, Perivoliotis D
    Promoting recovery among persons with schizophrenia using Recovery-Oriented Cognitive Therapy (CT-R).
    Schizophr Res. 2022;250:125-126.
    PubMed        

  34. BECKER WRIGHT ML, Ahmed AO, Barchard KA, Benning SD, et al
    Latent structure of cognitive tests is invariant in men and women with schizophrenia.
    Schizophr Res. 2022;250:127-133.
    PubMed         Abstract available

  35. CAROFF SN, Ungvari GS, Gazdag G
    Treatment of schizophrenia with catatonic symptoms: A narrative review.
    Schizophr Res. 2022 Nov 17:S0920-9964(22)00431.
    PubMed         Abstract available

  36. MILLER BJ, McEvoy JP, McCall WV, Lu XY, et al
    Lower adiponectin levels as a predictor of depressive symptoms in African-American males with schizophrenia.
    Schizophr Res. 2022;250:134-136.
    PubMed        

  37. DJORDJEVIC M, Brink V, Wardenaar KJ, Scholte-Stalenhoef AN, et al
    Personality traits and coping strategies in recent-onset psychosis: Associations with symptom severity and psychosocial functioning.
    Schizophr Res. 2022;250:143-151.
    PubMed         Abstract available

  38. SCHORR B, Clauss JME, de Billy CC, Dassing R, et al
    Subtyping chronic catatonia: Clinical and neuropsychological characteristics of progressive periodic catatonia and chronic system catatonias vs. non-catatonic schizophrenia.
    Schizophr Res. 2022 Nov 18:S0920-9964(22)00392.
    PubMed         Abstract available

  39. MOLSTROM IM, Nordgaard J, Urfer-Parnas A, Handest R, et al
    The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies.
    Schizophr Res. 2022;250:152-163.
    PubMed         Abstract available

  40. RASMUSSEN AR, Zandersen M, Nordgaard J, Sandsten KE, et al
    Pseudoneurotic symptoms in the schizophrenia spectrum: An empirical study.
    Schizophr Res. 2022;250:164-171.
    PubMed         Abstract available

  41. ZHAO Q, Wang WQ, Fan HZ, Li D, et al
    Vocal acoustic features may be objective biomarkers of negative symptoms in schizophrenia: A cross-sectional study.
    Schizophr Res. 2022;250:180-185.
    PubMed         Abstract available

  42. KHAN A, Lindenmayer JP, Insel B, Seddo M, et al
    Computerized cognitive and social cognition training in schizophrenia for impulsive aggression.
    Schizophr Res. 2022 Nov 21:S0920-9964(22)00418.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: